SAN FRANCISCO, April 13, 2011 /PRNewswire/ -- endpoint Clinical (www.endpointclinical.com), a leader in Integrated Voice Response (IVR)/Integrated Web Response (IWR) systems, announced today that it has partnered with OmniComm Systems, Inc. (OTC: OMCM.OB), one of the fastest growing companies in the EDC marketplace, to provide an integrated method of capturing and transferring data for clinical trials that reduces redundancy in data entry and improves the speed at which a clinical trial can take place.
endpoint's flagship product platform, PULSE, is fully configurable, allowing users to design and deploy clinical trial Integrated Response Technology (IRT) systems and saves 40 percent on the development time of clinical trials.
The partnership of endpoint and OmniComm can:
- Reduce the number of systems that access the data
- Eliminate duplicate data entry through the sharing of data
- Streamline the flow of information
- Enable dual site activation by exchanging data for screening
- Remove duplication of data entry and eliminate data entry errors: Enter data once!
"It's a fact that EDC companies don't do IVR as well and likewise, IVR companies don't do EDC as well," said Jonathan Dole, co-founder and CEO, endpoint. "We're specialists in our field, yet we think that when coupled with an EDC leader like OmniComm, we're both better. Traditionally, integration can be tough in this business, and we believe that clinical trial program managers will have the best of both worlds and be much better off because of how endpoint and OmniComm are able to integrate at a deep level."
"We are very happy to be working with endpoint to offer our customers an integrated solution to improve clinical trial efficiency, reduce timelines, and drive down operational costs," said Stephen Johnson, President and COO of OmniComm. "By working together, we allow program managers to spend more time managing a study with less time spent trying to manage the data."
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
endpoint is an innovative company dedicated to the development of the leading technology platforms for the life sciences industry. endpoint's founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma for domestic and global studies with experience across a broad range of therapeutic areas and global implementations. For more information, visit endpoint at www.endpointclinical.com.
SOURCE endpoint Clinical